October 22, 2020         
InventHelp Inventor Develops Improved Sanitary Pad Product for Women (PND-5067)   •   Two Bit Circus Launches REMOTE: A Customizable, Play-From-Home Game Show, Hosted Live For Groups Of All Sizes   •   Tonal Announces Smart Flex, the Newest Dynamic Weight Mode in its Suite of Intelligent Weight Training Features   •   Black Women Leaders Host Statewide Call to Action in Support of Pro-Black Initiatives: Prop 15, Prop 16 and Prop 21   •   Community Wellness Launches in California to Bring Remote Patient Monitoring Service to Older Adults with Cardiovascular Disease   •   FIBRA Prologis Receives Investment Grade Credit Rating   •   Women 20 (W20) Challenges G20 Leaders to Close the Gap Between Imagination and Reality on Women’s Equality   •   Analytics Insight Announces 'The 10 Most Influential Women in Technology 2020'   •   Mini Golf, Monsters, Music and Fun Rolls into Ridge Hill in Yonkers, NY - Now Open   •   Kilburn Live Teams Up With Dr. Seuss Enterprises For Brand New Holiday Experience Fit For Celebrating The 2020 Yuletide Season   •   Morgan Stanley Launches Program to Provide Full Scholarships to Spelman College Students   •   PredictSpring Partners With Deciem Expanding Modern POS to Beauty Industry   •   New COVID-19 Projections Show No Signs of Outbreak Abating in Midwest & Mountain States   •   FIBRA Prologis Announces Third Quarter 2020 Earnings Results   •   America Will Rally for Afterschool Tomorrow as 21st Annual Lights On Afterschool Events Are Held Across the Country   •   Local Businesses Holding Relief Drive For Lake Charles Hurricane Survivors   •   Coty Builds Digital & Luxury Strength With New Executive Appointments   •   Clo-Clo Vegan Foods New Full Line of Plant-Based Pizzas Adds a Novel Ingredient to the Recipe: Flavor!   •   Consumers Demand Alcohol Cancer Warning Labels   •   shopDisney.com|Disney Store Unveil the Top 15 Toys for the 2020 Holiday Season
Bookmark and Share

Celmatix Announces New Advisory Board

NEW YORK , September 23 /Businesswire/ - Celmatix Inc., the leading women’s health biotech focused uniquely on ovarian biology, today announced members of its newly appointed Advisory Board. The interdisciplinary new board includes thought leaders from biopharma, technology, and women’s health. This team will play an instrumental role in supporting the continued success of Celmatix’s lead ovarian senescence drug program as it progresses through preclinical development and its platform partnerships.

Celmatix Founder and CEO, Dr. Piraye Yurttas Beim commented, “We are excited to be convening this incredible team of clinicians and industry veterans through our Advisory Board.” She continued, “Several recent high-profile exits in this therapeutic area, in addition to long-term demographic trends, have created demand for a novel pipeline of therapies in women’s health. However, underinvestment in women’s health R&D over the last few decades has led to a limited pipeline of existing assets. Celmatix has amassed an unprecedented multi-omic data set focused on ovarian biology, which has given us unique insights into the key molecules and pathways underlying ovarian function. The retained and partnered drug programs that have resulted from this platform have the potential to catalyze a new era of women’s health, and we know the guidance of a seasoned team of advisors will be key to capitalizing on this unique opportunity.”

Members of the Advisory Board include:

Linda C. Giudice, MD, PhD; Distinguished Professor, Chair Emerita, and the Robert B. Jaffe MD Endowed Professor in the Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco (UCSF). She is a biochemist and reproductive endocrinologist specializing in endometriosis, ovulatory disorders, and infertility.

Amber Cooper, MD, MSCI, FACOG; Reproductive Endocrinologist and Medical and IVF Practice Director of Vios Fertility Institute St. Louis. She is board certified in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and speaks nationally and internationally on ovarian aging, primary ovarian insufficiency, genetics, and how cancer and autoimmune disease therapies affect reproductive health and fertility.

Steve England; More than 25 years of drug discovery experience with senior R&D leadership roles at Pfizer, AstraZeneca, and AbbVie. He has personally led drug discovery programs and managed large teams of drug hunters involved in target identification, validation, and prosecution up to and beyond the clinical candidate stage.

Mark Wolters; Previously Vice President of Business Development at Bayer where he led a team of early-stage licensing and transaction professionals and has more than 25 years of pharmaceutical industry experience. In addition to Celmatix, he also serves on the Advisory Board of the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany.

Kevin Lynch; Vice President of Business Development at Vir Biotechnology, and previously Chief Business Officer at Recursion Pharmaceuticals and VP and Head of the Global Search and Evaluation group at AbbVie. He also worked in additional business development roles at Abbott/AbbVie and led many successful transactions to grow the companies’ therapeutics portfolio.

Cory Ondrejka; Vice President of Product Management and Technical Advisor to the CEO at Google. Previously, he led the mobile transition at Facebook as Vice President of Engineering where he also led Facebook’s multi-billion dollar acquisition and integration of Oculus VR. Cory was also the Chief Technology Officer of Linden Lab, where he co-created the award-winning virtual world Second Life.

This news follows Celmatix’s announcement that the company had reached a second milestone in its five-year, multi-target alliance with Evotec. This milestone was triggered by Bayer advancing a second drug program centered around a novel Celmatix-identified target from Evotec. The first milestone was announced in June 2020, and was triggered by Bayer advancing the first drug program centered around a novel Celmatix-identified target from Evotec.

The newly appointed Advisory Board will work closely with Dr. Beim and the Celmatix Executive Team as the Company progresses internally developed programs and collaborations with its marquee partners.

About Celmatix

Celmatix is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead program in ovarian senescence and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. For more information visit www.celmatix.com.

STORY TAGS: Research, Women, Biotechnology, Other Health, Health, Consumer, Pharmaceutical, General Health, Science, Personnel, United States, North America, New York,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News